engleski

The influence of sugammadex on glycaemic status

Sugammadex is a novel muscle relaxant binding agent. Although it has been generally considered to have no effect on the metabolism of glucose in humans, there is no clear evidence confirming this belief. The aim of this prospective, interventional, randomized and one-side blind study was to assess the effect of sugammadex on postoperative blood glucose values in adult patients. After signing the informed consent form, 82 nondiabetic adults scheduled for elective septoplasty were randomly assigned to two groups according to the agent administrated at the end of surgery for reversal of neuromuscular blockade: sugammadex (study group) or neostigmine/atropine (control standard care group). Primary outcome was the postoperative blood glucose value. Secondary outcome was the efficacy of neuromuscular blockade reversal: extubation time, time to transfer to the ward, recovery of muscle strength, patient mobility and patient mobilization. The results confirmed a statistically significant difference in postoperative blood glucose values at one hour (P=0.023) and two hours (P=0.015) after the administration of sugammadex compared to the control group. All blood glucose values were within the clinically acceptable values that did not require treatment. Extubation time (2 minutes vs. 4 minutes, P<0.001) and time to transfer to the ward (3 minutes vs. 9 minutes, P<0.001) were shorter after the administration of sugammadex. Compared to neostigmine, sugammadex showed greater clinical efficacy within the first 15 minutes in the recovery of muscle strength (head lifting, tongue protrusion and wide eyes opening test) and the test of mobility. This study showed sugammadex to increase blood glucose after septoplasty, but this increase did not exceed clinically acceptable values. There is no need for the clinicians to implement special glucose control measures if using sugammadex to neutralize rocuronium in adult nondiabetic patients.

sugamadex, glicemia

nije evidentirano